Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceSin categoríaVideos

European Commission approves elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory myeloma

  European Commission (EC) has approved elotuzumab  –marketed under the brand Empliciti by Bristol-Myers Squibb (BMS)– plus pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI), and have demonstrated disease progression on…

Read more

Lenalidomide and pomalidomide based triplet combination regimens for myeloma patients receives approval from the European Commission

The European Commission has approved two of Celgene’s IMiD ® -based combination regimens: Lenalidomide (Revlimid®) in combination with bortezomib and dexamethasone (RVd) in adult patients with previously untreated multiple myeloma who are not eligible for transplant Pomalidomide (Imnovid®) in combination with bortezomib and dexamethasone (PVd), in adult patients with multiple myeloma, who have received at…

Read more

Results of MPE members participation in EMA survey on bortezomib

As bortezomib, an anti-myeloma medicine, is licensed as both an intravenous (IV – through the vein via a drip) and subcutaneous medicine (through the skin, via an injection), the European Medicines Agency (EMA) recently conducted a survey to understand which method was most commonly used across Europe. They also asked about the location of administration…

Read more

Myeloma Patients Europe webinar on CAR-T cell treatment

Patient advocates, patients and caregivers have heard a lot about CAR-T cell treatment and its potential in myeloma. However, there are still a lot of questions about its benefits, its challenges and its role in treating myeloma. With the aim of providing an overview of CAR-T cell treatment in myeloma, healthcare professional expectations and an…

Read more

ASH 2018 highlights in myeloma

Myeloma Patients Europe held a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2018.

Read more
August

September 2026

October
MO
TU
WE
TH
FR
SA
SU
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
4
Events for 1st September
No Events
Events for 2nd September
No Events
Events for 3rd September
No Events
Events for 4th September
No Events
Events for 5th September
No Events
Events for 6th September
No Events
Events for 7th September
No Events
Events for 8th September
No Events
Events for 9th September
No Events
Events for 10th September
No Events
Events for 11th September
No Events
Events for 12th September
No Events
Events for 13th September
No Events
Events for 14th September
No Events
Events for 15th September
No Events
Events for 16th September
No Events
Events for 17th September
No Events
Events for 18th September
No Events
Events for 19th September
No Events
Events for 20th September
No Events
Events for 21st September
No Events
Events for 22nd September
No Events
Events for 23rd September
No Events
Events for 24th September
No Events
Events for 25th September
No Events
Events for 26th September
No Events
Events for 27th September
No Events
Events for 28th September
No Events
Events for 29th September
No Events
Events for 30th September
No Events